If you are wondering whether Exponent is fairly priced or offering value right now, you are in the right place for a clear, ...
JP Morgan recently initiated coverage on Exponent with an Overweight/Buy rating, highlighting the firm’s position as a leading science and engineering consulting company and expressing confidence in ...
StockStory.org on MSN
Exponent’s (NASDAQ:EXPO) Q4 CY2025: Strong sales
Scientific consulting firm Exponent (NASDAQ:EXPO) reported in Q4 CY2025, with sales up 19.1% year on year to $147.4 million. Its GAAP profit of $0.49 per share was 3.7% above analysts’ consensus ...
Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results